Creating a new generation of small molecule protease inhibitors

Slide 1

KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs.

Slide 2

KalVista is developing plasma kallikrein inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME); indications where excessive plasma kallikrein activity is implicated, but where there remains substantial unmet clinical need.

Slide 3

KalVista continues to investigate additional proteases as potential therapeutic targets to fully exploit its research expertise and expand its portfolio.

Slide 4

The Company features an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with proven experience in bringing small molecules through the clinic to commercialization.

News

KalVista Pharmaceuticals Presents Data at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

29 May 2018 Read more...

KalVista Pharmaceuticals Presents Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting

2 May 2018 Read more...